Tempus AI (TEM) Is Building a Heart Failure Agent That Never Sleeps

Tempus AI (TEM) has been awarded up to $9.5 million by the US health research agency ARPA-H to develop an AI that manages heart failure patients without direct oversight from a clinician. This is not just about the money; it's about where Tempus wants to direct its data and software next. Heart failure affects over 6 million Americans, and nearly half do not survive five years after diagnosis, despite available life-extending treatments.

Currently, under 25% of patients receive all recommended therapies, and nearly 46% of US counties have no practicing cardiologist. Tempus believes that software can bridge this gap in healthcare. Its proposed agent would monitor hospital records and home heart rate monitors continuously, then communicate directly with patients regarding symptoms, medications, virtual rehabilitation, and scheduling appointments, all while updating medical records accordingly.

Tempus is not starting from scratch; its care-gap tool, Tempus Next, has analyzed data from over 2.7 million cardiology patients, and the company holds three FDA-cleared ECG products designed to identify undiagnosed heart disease. Meanwhile, the core business of Tempus is showing positive momentum. For the quarter ending June 30, revenue increased by 22% to $382.5 million, driven by a 31% increase in oncology testing volume.

Additionally, data licensing grew an impressive 36%, with drugmakers continuing to pay for Tempus's collected data. With $820.7 million in cash and marketable securities, Tempus has the financial capacity to invest in the development of the heart failure agent without relying on grants. However, this is still a plan, not a fully developed product.

The trial must demonstrate that the agent is both safe and effective before it can be sold. Despite the potential of Tempus in the AI space, there are concerns. The ARPA-H award is a significant investment, but it is a ceiling for the funding. The company's financials indicate that much of the income in the June quarter was due to unrealized gains on marketable securities, and the loss from operations widened by 23% compared to the previous year.

Furthermore, the planned acquisition of Personalis, valued at approximately $1.5 billion, adds big commitments to Tempus's already thin profit picture. This acquisition is expected to close in late Q4 2026 or early 2027, and the guidance does not include the deal. The sentiment towards Tempus is mixed, with hedge fund ownership rising to 38 funds from 33 in the latest quarter, indicating strong interest.

However, 29.17% of the float is sold short, reflecting significant skepticism and a large amount of money wagering that the growth story might not succeed. The combination of a promising idea, a strong core business in data licensing, and a robust financial position gives Tempus potential as an investment. Nevertheless, bulls will need the trial for the autonomous heart failure agent to show safe and effective care for this to be realized, while bears are watching the widening operating losses and the impact of the large acquisition on Tempus's financial health.